-
Je něco špatně v tomto záznamu ?
Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD - a prospective interventional study
A. Vašura, E. Machytka, O. Urban, J. Macháčková, L. Pavliska, Z. Berka, Z. Švagera, M. Bužga
Jazyk angličtina
Typ dokumentu klinické zkoušky, časopisecké články
NLK
Directory of Open Access Journals
od 2019
Medline Complete (EBSCOhost)
od 2013-11-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- bariatrická chirurgie * MeSH
- časové faktory MeSH
- design vybavení MeSH
- dospělí MeSH
- elastografie MeSH
- hmotnostní úbytek MeSH
- jaterní cirhóza * etiologie diagnostické zobrazování diagnóza MeSH
- lidé středního věku MeSH
- lidé MeSH
- nealkoholová steatóza jater * diagnostické zobrazování diagnóza etiologie MeSH
- obezita * komplikace chirurgie diagnóza MeSH
- pilotní projekty MeSH
- prospektivní studie MeSH
- výsledek terapie MeSH
- žaludeční balónek * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
INTRODUCTION AND OBJECTIVES: With increases in obesity and metabolic syndrome because of lifestyle-related factors, the prevalence of non-alcoholic fatty liver disease (NAFLD) also is increasing worldwide. In a subset of patients with NAFLD, an inflammatory process arises in the steatotic liver, known as non-alcoholic steatohepatitis, that leads to liver fibrosis and liver cirrhosis. In selected patients with obesity, bariatric surgery, and bariatric endoscopy are important therapeutic options. MATERIALS AND METHODS: This prospective interventional pilot study was conducted to investigate two types of intragastric balloons (IGB). The IGBs were the Orbera and the Spatz3. Liver fibrosis changes were monitored non-invasively using point and 2D shear wave ultrasound elastography (SWE) and transient elastography that allowed for quantification of liver steatosis using the controlled attenuation parameter (CAP). Patients were followed for 12 months. RESULTS: Of 34 patients implanted with an IGB, 30 completed follow-up at month 12; results for one patient were excluded because of initiation of obesity pharmacotherapy. Fifteen patients received the Orbera IGB, and nineteen patients received the Spatz3 type. In month 12, total and excess weight loss was 7.88 % and 30.13 %. Elastography values decreased from baseline (3.88 kPa) to 3.61 kPa at month 12 (p 0.024). 2D SWE values decreased from baseline (5.42 kPa) to a value of 4.91 kPa at month twelve (p 0.135). Transient elastography values decreased from baseline (5.62 kPa) to a value of 4.17 kPa at month twelve (p 0.009). CONCLUSIONS: Bariatric endoscopy in the form of IGB implantation leads to weight reduction and improvement of liver fibrosis and steatosis. GOV REGISTRATION: NCT04895943.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25016432
- 003
- CZ-PrNML
- 005
- 20250731092909.0
- 007
- ta
- 008
- 250708s2025 mx f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.aohep.2024.101765 $2 doi
- 035 __
- $a (PubMed)39674369
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a x
- 100 1_
- $a Vašura, Adam $u Department of Internal Medicine and Cardiology, Division of Gastroenterology, hepatology and pancreatology, University Hospital Ostrava, 17. Listopadu 1740, 70800, Ostrava, Czech Republic; Department of Clinical Studies, Faculty of Medicine, University of Ostrava, Syllabova 19, 70030, Ostrava, Czech Republic. Electronic address: vasuraadam@seznam.cz
- 245 10
- $a Effect of bariatric endoscopy on liver fibrosis and steatosis and the course of NAFLD - a prospective interventional study / $c A. Vašura, E. Machytka, O. Urban, J. Macháčková, L. Pavliska, Z. Berka, Z. Švagera, M. Bužga
- 520 9_
- $a INTRODUCTION AND OBJECTIVES: With increases in obesity and metabolic syndrome because of lifestyle-related factors, the prevalence of non-alcoholic fatty liver disease (NAFLD) also is increasing worldwide. In a subset of patients with NAFLD, an inflammatory process arises in the steatotic liver, known as non-alcoholic steatohepatitis, that leads to liver fibrosis and liver cirrhosis. In selected patients with obesity, bariatric surgery, and bariatric endoscopy are important therapeutic options. MATERIALS AND METHODS: This prospective interventional pilot study was conducted to investigate two types of intragastric balloons (IGB). The IGBs were the Orbera and the Spatz3. Liver fibrosis changes were monitored non-invasively using point and 2D shear wave ultrasound elastography (SWE) and transient elastography that allowed for quantification of liver steatosis using the controlled attenuation parameter (CAP). Patients were followed for 12 months. RESULTS: Of 34 patients implanted with an IGB, 30 completed follow-up at month 12; results for one patient were excluded because of initiation of obesity pharmacotherapy. Fifteen patients received the Orbera IGB, and nineteen patients received the Spatz3 type. In month 12, total and excess weight loss was 7.88 % and 30.13 %. Elastography values decreased from baseline (3.88 kPa) to 3.61 kPa at month 12 (p 0.024). 2D SWE values decreased from baseline (5.42 kPa) to a value of 4.91 kPa at month twelve (p 0.135). Transient elastography values decreased from baseline (5.62 kPa) to a value of 4.17 kPa at month twelve (p 0.009). CONCLUSIONS: Bariatric endoscopy in the form of IGB implantation leads to weight reduction and improvement of liver fibrosis and steatosis. GOV REGISTRATION: NCT04895943.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a bariatrická chirurgie $7 D050110
- 650 _2
- $a elastografie $7 D054459
- 650 _2
- $a design vybavení $7 D004867
- 650 12
- $a žaludeční balónek $7 D015905
- 650 12
- $a jaterní cirhóza $x etiologie $x diagnostické zobrazování $x diagnóza $7 D008103
- 650 12
- $a nealkoholová steatóza jater $x diagnostické zobrazování $x diagnóza $x etiologie $7 D065626
- 650 12
- $a obezita $x komplikace $x chirurgie $x diagnóza $7 D009765
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a hmotnostní úbytek $7 D015431
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Machytka, Evžen $u Department of Internal Medicine and Cardiology, Division of Gastroenterology, hepatology and pancreatology, University Hospital Ostrava, 17. Listopadu 1740, 70800, Ostrava, Czech Republic. Electronic address: evmac@seznam.cz
- 700 1_
- $a Urban, Ondřej $u Department of Internal Medicine II - Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Zdravotníků 248/7, 779 00, Olomouc, Czech Republic. Electronic address: ondrej.urban@fnol.cz
- 700 1_
- $a Macháčková, Jitka $u Department of Epidemiology and Public Health, Faculty of Medicine, University of Ostrava, Syllabova 19, 70030, Ostrava, Czech Republic. Electronic address: machackova@endohope.cz
- 700 1_
- $a Pavliska, Lubomír $u Research and Education department, University Hospital Ostrava, 17. Listopadu 1740, 70800, Ostrava, Czech Republic. Electronic address: lubomir.pavliska@fno.cz
- 700 1_
- $a Berka, Zdeněk $u Department of Internal Medicine II - Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital, Zdravotníků 248/7, 779 00, Olomouc, Czech Republic. Electronic address: zdenek.berka@fnol.cz
- 700 1_
- $a Švagera, Zdeněk $u Institute of Laboratory Medicine, University Hospital Ostrava,17. Listopadu 1740, 70800, Ostrava, Czech Republic. Electronic address: zdenek.svagera@fno.cz
- 700 1_
- $a Bužga, Marek $u Institute of Laboratory Medicine, University Hospital Ostrava,17. Listopadu 1740, 70800, Ostrava, Czech Republic; Department of Physiology and Pathophysiology, Faculty of Medicine, University of Ostrava, Syllabova 19, 70030, Ostrava, Czech Republic. Electronic address: marek.buzga@osu.cz
- 773 0_
- $w MED00172549 $t Annals of hepatology $x 1665-2681 $g Roč. 30, č. 1 (2025), s. 101765
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39674369 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731092904 $b ABA008
- 999 __
- $a ok $b bmc $g 2366936 $s 1253557
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 30 $c 1 $d 101765 $e 20241212 $i 1665-2681 $m Annals of hepatology $n Ann Hepatol $x MED00172549
- LZP __
- $a Pubmed-20250708